Clinical Trials Logo

Clinical Trial Summary

exercise and physical activity can have an anti-inflammatory effect, while there is evidence that a sedentary lifestyle could be the basis for the development of systemic inflammation and increased cardiovascular risk. The primary objective is to assess whether regular physical activity is able to induce a decrease in systemic immune-activation in HIV positive patients.


Clinical Trial Description

Many studies document that exercise and physical activity can have an anti-inflammatory effect, while there is evidence that a sedentary lifestyle could be the basis for the development of systemic inflammation and increased cardiovascular risk. This occurs because a sedentary lifestyle leads to the accumulation of visceral fat, and this is accompanied by an increase in adipokine release and infiltration of adipose tissue by the pro-inflammatory immune cells. Furthermore, the imbalance between immune processes and metabolic processes is associated with the development of insulin resistance, atherosclerosis and neurodegeneration.

The primary objective is to assess whether regular physical activity is able to induce a decrease in systemic immune-activation in HIV positive patients.

To evaluate this hypothesis, the following parameters will be analyzed: evaluation of immune-activation levels, of metabolic parameters, of cardiac function, of immuno-virological set-up, of dietary intake and of physical performance indices in HIV-positive patients with a sedentary lifestyle; these data will be compared with the values measured in the same HIV positive population with a sedentary lifestyle after three months of regular physical activity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03392805
Study type Interventional
Source University of Roma La Sapienza
Contact Gabriella d'Ettorre, MD PhD
Phone +39-06-49970324
Email gabriella.dettorre@uniroma1.it
Status Recruiting
Phase N/A
Start date January 1, 2016
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women Phase 2/Phase 3
Recruiting NCT03416790 - IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment
Recruiting NCT03570918 - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy Phase 1
Not yet recruiting NCT03624413 - InTSHA: Interactive Transition Support for HIV-infected Adolescents Using Social Media N/A
Recruiting NCT03536234 - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients Phase 2
Not yet recruiting NCT03549689 - Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) Phase 2
Not yet recruiting NCT03705169 - Pharmacokinetics of SAR441236 Phase 1
Active, not recruiting NCT03251690 - Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression N/A
Recruiting NCT03532425 - B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults Phase 4
Not yet recruiting NCT03709355 - Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs Phase 1
Not yet recruiting NCT03580668 - Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide
Not yet recruiting NCT03199690 - A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers Phase 1
Active, not recruiting NCT01466582 - Comorbidity and Aging With HIV N/A
Recruiting NCT03148964 - Primary Infection Cohort N/A
Recruiting NCT03512210 - Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection Phase 4
Recruiting NCT03706898 - Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs Phase 1
Active, not recruiting NCT03312244 - Pyridostigmine as Immunomodulator in People Living With HIV Phase 2
Withdrawn NCT03074786 - Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH) Phase 2
Recruiting NCT03539224 - Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept. Phase 2
Completed NCT03226873 - Peer Outreach and Navigation Intervention to Increase PrEP Uptake Among Women at High Risk for HIV N/A